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ABSTRACT  We  have  demonstrated  in vitro and  in vivo  the specific  binding of a monoclonal 
antibody  to the  rat  nerve  growth  factor  (NGF)  receptor.  Previous  work had  shown that this 
antibody,  designated  192-1gG, does not compete with  NGF for binding to the NGF receptor 
of PC12 cells,  but instead  interacts with the  receptor to  increase  NGF binding to  PC12 cells 
(Chandler, C. E., L. M. Parsons, M. Hosang, and E. M. Shooter,  1984, J. Biol. Chem., 259:6882- 
6889).  In the present study, a solid-phase separation assay verified the specific formation of a 
ternary complex  of  192-1gG, the  NGF  receptor,  and  NGF:  12Sl-labeled 192-1gG precipitated 
from  solution  only when incubated  with  both solubilized  NGF receptor and  NGF covalently 
linked to a solid  phase (Sepharose  4B). Filtration assays using  plasma  membrane preparations 
of various tissues showed strict correlation of 1251-192-1gG and 12Sl-labeled NGF binding; only 
membranes  obtained  from  superior  cervical  ganglion  bound  significant  amounts  of  the 
monoclonal antibody and  NGF. Injection of 1~51-192-1gG into the rat anterior eye chamber led 
to  accumulation  of  intact  antibody  molecules  in  the  ipsilateral  superior  cervical  ganglion, 
indicating  retrograde  axonal  transport  of 12Sl-192-1gG from  the  neuronal  termini,  located  at 
the iris, to the cell bodies situated  in the ganglion. The time course and saturation character- 
istics  of ~251-192-1gG retrograde  transport were very similar to those  previously  reported  for 
~251-NGF transport,  indicating that  192-1gG can  be internalized  and transported  by the same 
mechanisms  as  is  NGF.  Consistent  with  results  of the  in  vitro  binding  assays, 192-1gG and 
NGF failed to compete for retrograde transport and were actually co-transported.  Retrograde 
axonal transport of 192-1gG appears  to be species specific,  since  ~251-192-1gG  was transported 
in the rat, but not in mice, gerbils,  hamsters, or guinea pigs. These results establish  monoclonal 
antibody  192-1gG as a specific  probe for the rat NGF receptor in vitro and in vivo. 
Nerve  growth  factor (NGF) ~ is  a  polypeptide  neurotrophic 
agent that is essential  for survival and maintenance of sym- 
pathetic neurons and some sensory neurons, both in vivo and 
in dissociated cell culture (for review see references  1 and 2). 
Organs  innervated  by  sympathetic  nerves  produce  minute 
quantities  of NGF (3),  which binds to specific receptors on 
the  neurons' terminal  fibers.  NGF is then  internalized  and 
retrogradely transported  within  the axons to the cell bodies 
(4-6). The biochemical events through which NGF promotes 
neuronal survival and function are, as yet, unknown. 
Abbreviations  used in  this paper.  EGF, epidermal growth factor; 
NGF, nerve growth factor; SCG, superior cervical ganglion (ganglia). 
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The NGF receptor must play at least one critical role in the 
biology of NGF,  namely,  binding  the  factor to  the  proper 
neuronal termini and thereby targeting it to the appropriate 
cells.  By analogy to the  functions  described  for the  insulin 
receptor (7) and the epidermal growth factor (EGF) receptor 
(8),  the NGF receptor may be directly involved in mediating 
at least some of the biological effects of NGF.  Specific NGF 
receptors are found in superior cervical ganglion (SCG) neu- 
rons (9),  dorsal root ganglion neurons (10), and some other 
cells of neural crest origin, in particular melanomas ( 11 ) and 
the PC 12 cell line from a rat pheochromocytoma (12). Many 
binding data have been accumulated, and there is a report of 
the  purification  of the  receptor  from  a  human  melanoma 
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vivo actions of the NGF receptor. A  tool useful in obtaining 
such information would be a  ligand that binds specifically to 
the NGF receptor, but which, unlike NGF itself, is not nor- 
mally required by the cells for survival. 
A  monocional antibody,  designated  192-IgG,  was devel- 
oped  as  a  specific  probe  for  the  NGF  receptor  (14).  The 
hybridoma clone was generated by the fusion of Sp2/O-Agl4 
myeloma cells with BALB/c splenocytes from mice immu- 
nized with detergent-solubilized plasma membrane proteins 
of  PC12  cells.  192-IgG  does  not  bind  NGF,  nor  does  it 
compete with NGF for binding to PC 12 cells. Consistent with 
192-IgG  specifically binding to  only the NGF  receptor, the 
antibody binds to the same number of sites on PC12 cells as 
does  NGF,  and  it  increases the  apparent  affinity  of NGF 
binding by  2.5-  to  4-fold.  Cross-linking of ~25I-labeled  192- 
IgG to PC 12 cells using hydroxysuccinimidyl-4-azidobenzoate 
and  subsequent polyacrylamide electrophoresis and autora- 
diography led to the appearance of a major band of molecular 
weight  160,000;  this molecular weight is consistent with the 
cross-linking of one heavy and one light chain of 192-IgG (a 
total  Mr  of 75,000)  to  the  NGF  receptor  (Mr  =  74,000). 
Antigen  detection  using  a  protein  transfer  technique  (15) 
failed to produce further evidence that the 192-IgG binds the 
NGF  receptor itself and  not a  separate cell  surface protein 
which is present in equal numbers to the NGF receptor and 
which  interacts  with  the  receptor  protein.  These  results 
strongly suggested, but did not prove, that the antibody binds 
to  the  NGF  receptor molecule;  the  192-IgG  was  therefore 
termed an "NGF receptor interactive monoclonal antibody." 
We have performed experiments  to demonstrate the specific 
binding of monoclonal antibody  192-IgG to NGF receptors 
in  vitro  and  in  vivo.  A  solid-phase separation  assay  using 
solubilized plasma membrane proteins of rat SCG indicated 
the simultaneous binding of 192-IgG and NGF to the NGF 
receptor.  Binding  of  the  monoclonal  antibody  to  plasma 
membrane preparations from  various  tissues  showed  strict 
correlation with NGF binding. Retrograde transport of intra- 
ocularly injected ~25I-NGF is a  well-documented process that 
involves the binding of  the protein to its receptor on the nerve 
termini, internalization into the neuron, and active vectorial 
translocation to  the  cell  body  (2,  4,  16).  Our  experiments 
revealed retrograde transport of ~2sI-192-IgG with character- 
istics similar to that of ~2~I-NGF.  We conclude that the  192- 
IgG is a specific probe for the NGF receptor both in vitro and 
in vivo. Some of  the experiments reported here have appeared 
in an abstract (17). 
MATERIALS 
The 2.5S subunit of NGF was used in all experiments; it was purified from 
adult male mouse submaxillary glands according to the method of Bocchini 
and  Angeletti (18). The  monoclonal antibody,  192-1gG, was purified from 
ascites by ammonium sulfate precipitation (50%) followed  by anion exchange 
chromatography on DEAE Sephacel (Pharmacia Fine Chemicals, Piscataway, 
NJ) (19) and gel filtration on a Sephacryl S-200 column (1.5 cm I.D. ×  l l6 
cm) equilibrated with PBS (20 mM K2HPO4, 160 mM NaCl, pH 7.4). The A 
chain protein subunit of ricin toxin was purified from castor beans (Hummert 
Seed Co, St. Louis, MO) as described previously  (20, 21); NGF, 192-IgG, and 
ricin A chain were >95% pure, as assessed  by SDS PAGE (22). Electrophoresis 
reagents were obtained from Bio-Rad Laboratories, Richmond, CA. All other 
chemicals, unless noted, were purchased from Sigma Chemical Co., St. Louis, 
MO. 
Iodination  Procedure:  Both  NGF and  192-1gG were iodinated by 
the lactoperoxidase  method (23), as previously described (24). 10 #g of NGF 
or  100 ug of 192-1gG were each reacted with  1 mCi of Na~251 (Amersham 
Corp., Arlington Heights, IL). The amount of incorporation of 1-125 into the 
proteins ranged from 70 to 90%, corresponding  to specific  activities  of 1.8-2.3 
Ci/umol for NGF and 1.1-1.4 Ci/#mol for 192-IGG. For use in binding assays 
the labeled ligands  were separated from non-incorporated 1-125 by chromatog- 
raphy on Sephadex  G-25 M (PD-10 columns; Pharmacia Fine Chemicals).  The 
~25I-NGF was further processed  by filtration through an Amicon Centrifio 50A 
membrane (pre-soaked in  PBS/0.1% Triton  X-100) to  remove aggregated 
molecules. 
Plasma  Membrane  Preparation:  The SCG were dissected from 
male Sprague-Dawley  rats weighing 150-175 g (Chappel Breeders, St. Louis, 
MO)  and  kept frozen at  -70"C  until use. A  plasma membrane-enriched 
microsomal fraction was prepared from 500-700 ganglia by the method of 
Costrini and Bradshaw (25). Tissues designated as controls were processed in 
the same manner. For use  in the filtration binding assay the  microsomal 
fraction was suspended in phosphate-buffered  saline (PBS). Solubilized NGF 
receptor (used in the solid-phase  separation assay) was obtained by adding to 
the suspended microsomal fraction sufficient n-octyl glucopyranoside  (1-O-n- 
octyl-/3-D-glucopyranoside;  Sigma Chemical  Co.) to achieve  a 2% final concen- 
tration, mixing for 1 h at room temperature, then centrifuging for 1 hour at 
100,000 g to remove insoluble material. Protein concentrations were deter- 
mined by the Lowry method (26). 
Coupling  of  NGF  or  Ricin  A  Chain  to  Sepharose 
4 B:  Sepharose 4B was activated by reacting it with cyanogen bromide (27): 
10 ml of the activated gel was combined with~8.1 mg of NGF in 250 mM 
sodium bicarbonate/500 mM NaCI, pH 8.5 (coupling  buffer). A 5-ml volume 
of gel was linked with 10 mg of ricin A chain in coupling buffer. The mixtures 
were turned end-over-end  for 6 h at room temperature, then overnight at 4"C. 
The solid phase of each mixture was pelleted by a  15-min centrifugation at 
1,000 g, and  the liquid was decanted. The amount  of NGF  remaining in 
solution was determined to be 0.80 mg by measuring the absorbance at 280 
nm (~ =  1.64); the amount coupled was therefore calculated to be 7.30 mg 
(90% efficiency). 7 mg of ricin A chain was linked to Sepharose  4B. The NGF- 
Sepharose  4B and ricin A chain-Sepharose  4B gels  were then each treated with 
10 ml of 0.2 M glycine in 100 mM sodium borate, pH 8.5, for 2 h. Finally, 
each gel was washed with two cycles  of coupling buffer followed  by 100 mM 
sodium acetate/500 mM NaC1, pH 4.5. 
Solid-Phase 5eparation Assay:  Detergent-solubilized  membrane 
proteins from rat superior cervical  ganglia (SCG) (10 zg) were mixed with ~251- 
192-IgG (50,000 cpm, ~25  fmol) in 0.5-ml microfuge tubes (Sarstedt, Inc., 
Princeton,  N  J) on ice for 2 hours. Each mixture also contained 1 mg/ml bovine 
serum albumin (BSA) and 2% n-octyl  glucopyranoside  in a final volume of 50 
ul. A 10-o3 aliquot of a 40% (vol/vol) slurry of NGF-Sepharose  4B was added 
and the mixture was allowed to equilibrate for an additional hour on ice; 
occasional vortexing  of  the tubes maintained the NGF-Sepharose  4B in suspen- 
sion. Each tube was then centrifuged in a Beckman microfuge B (Beckman 
Instruments, Inc., Palo Alto, CA) for 10 s to sediment the NGF-Sepharose  4B. 
The supernatant was aspirated, and the pellet was washed  three times with 150 
ul  of PBS/2% n-octyl glucopyranoside.  The radioactivity remaining in the 
NGF-Sepharose 4B pellet was measured in a Beckman 4000 gamma counter. 
To demonstrate that SCG membrane proteins are necessary to link the 1251- 
192-1gG to the NGF-Sepharose  4B, the SCG preparation was omitted, or was 
replaced with n-octylglucoside-solubilized  membrane proteins from rat liver 
( 100/zg per tube), or rat lung (30 #g). The specificity  of ~251-192-1gG binding to 
the SCG protein was tested by including  in the mixture an excess  of  nonlabeled 
192-1gG (200 pmol) or a control monoclonal IgG directed against the EGF 
receptor of PCI2 cells (200 pmol). To prove that ~251-192-IgG associates  with 
an SCG protein which binds specifically  to NGF, the NGF-Sepharose  4B was 
replaced with an equal volume of ricin A chain-Sepharose 4B, or, an excess  of 
either soluble NGF (1.3 nmol) or cytochrome c (1.5 nmol) was added concur- 
rently with the NGF-Sepharose  4B. 
Filtration Binding Assay:  The binding of J25I-NGF and 1251-192-1gG 
to the plasma membrane-enriched microsomal  fraction  obtained from different 
tissues  was assayed  by using  a modification  of  the method described  by Banerjee 
et al. (9). A membrane preparation (25 ug of protein) of rat SCG, spinal cord, 
adrenal, liver, lung, or skeletal muscle  was mixed with ~251-NGF ( 100,000 cpm) 
or ~251-192-1gG (900,000 cpm) in PBS/0.1% BSA in a total volume of 200 #l. 
After  40 min at 24"C, 3 ml of ice cold PBS/0.1% BSA/0.05% protamine sulfate 
was added to each tube and the entire contents were filtered  through a Millipore 
HVLP membrane by use of a Millipore manifold and a vacuum pump. Each 
filter was washed twice with 3-ml aliquots of the  PBS/0.1% BSA/0.05% 
protamine sulfate, and then measured for radioactivity.  Parallel assays  contain- 
ing excess  nonlabeled NGF (900-fold excess)  or nonlabeled 192-lgG (120-fold 
excess) determined the amount of nonspecifically  bound ~2~I-NGF or ~251-192- 
IgG, respectively. 
Retrograde Transport of 125 I-NGF and 12s I- 192-1gG:  Ligands 
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animals as previously described (16). The volumes injected were 5 #l for rats, 
and 2  ul for the other species.  Animals were  obtained as follows: Sprague- 
Dawley rats (200-225 g) from Chappel Breeders (St. Louis, MO), adult Swiss 
mice from Harlan Sprague-Dawiey,  Inc. (Indianapolis, IN),  adult gerbils from 
Tumblebrook Farms, Inc.  (West Brookfield,  MA), adult hamsters from Engle 
Laboratory Animals, Inc.,  (Farmersburg, IN),  and guinea pigs from Charles 
River Breeding Laboratories (Wilmington, MA). Animals  were killed by decap- 
itation, and both superior cervical  ganglia were  dissected and placed in the 
gamma counter. The radioactivity of the ganglion contralateral to the injected 
eye provided the background value attributable to spillover  of labeled  ligand 
into the systemic circulation. For analysis by SDS PAGE (22), each ganglion 
was homogenized in 1% SDS. 
RESULTS 
Solid-Phase Separation Assay 
Prior experiments had shown that 192-IgG enhances NGF 
binding to the NGF receptor (14),  but  only circumstantial 
evidence (as described in the introduction) existed that the 
monoclonal antibody itself actually bound to the NGF recep- 
tor. We sought to demonstrate 192-IgG binding to solubilized 
NGF receptor by the means of a solid-phase separation assay. 
Radioactive 192-IgG was combined with n-octyl glucopyran- 
oside-solubilized  membrane proteins  from SCG,  and  then 
NGF-Sepharose 4B was added to the mixture. If the mono- 
clonal antibody and NGF bind noncompetitively to the NGF 
receptor, a ternary complex consisting of ~251-192-IgG, NGF 
receptor,  and  NGF-Sepharose 4B  will  be  formed, and  the 
radioactivity would be bound indirectly, but specifically, to 
the NGF-Sepharose 4B. Bar b in Fig.  l depicts the radioactiv- 
ity that was associated with the final washed pellet when  l0 
#g of solubilized SCG membrane protein was incubated with 
~25  fmol  of 'zsI-192-IgG (50,000  cpm).  Bar  a  shows  the 
radioactivity pelleting from a  reaction containing no mem- 
brane preparation. This amount represents the  '251-192-IgG 
that  associates nonspecifically with  the  NGF-Sepharose 4B 
and therefore defines the background "noise" of this assay. 
This value from each separate experiment was used to nor- 
malize the results from other reaction conditions. We define 
the signal of the assay as the difference between the values of 
bars b and a. 
We tested the specificity of the  formation of the ternary 
complex by replacing two of the three components with other 
molecules, and by displacing either labeled antibody or NGF- 
Sepharose with excess nonlabeled antibody or soluble NGF, 
respectively. Substitution of the NGF-Sepharose 4B with an 
equal volume of Sepharose 4B coupled to the A chain of ricin 
reduced the radioactivity associated with the pellet to back- 
ground quantities (bar c). This result precluded the possibility 
that  the  signal  obtained  using  NGF-Sepharose 4B  (bar  b) 
resulted from the binding of 1251-192-IgG to a component of 
the solubilized SCG membrane preparation that  associated 
nonspecifically either with Sepharose 4B or with any protein 
molecule  linked  covalently  to  Sepharose  4B.  Addition  of 
soluble NGF (bar d) or nonlabeled  192-IgG (bar e), each in 
1,000-fold  excess of covalently-linked or iodinated  species, 
respectively, eliminated the signal. To show that this decrease 
in  recovered radioactivity represented specific inhibition  of 
the  formation of the  ternary complex, we  added  similarly 
excessive amounts of cytochrome c (a protein with  similar 
molecular weight and isoelectric point as NGF, burr) or of a 
monoclonal IgG directed against the EGF receptor of PC12 
cells (bar g); these proteins failed to reduce the radioactivity 
of the pellet.  Finally, we demonstrated the requirement for 
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FIGURE  1  Binding  of  1251-192-1gG to  solubilized  NGF  receptor. 
Radiolabeled 192-1gG was combined with n-octyl glucopyranoside- 
solubilized plasma membrane proteins of rat SCG,  liver, or  lung, 
with or without nonlabeled 192-1gG or a control monoclonal IgG, 
as described in Materials and Methods. After 2 h, NGF-Sepharose 
4B  or  ricin  A  chain-Sepharose  4B  was  added,  with  or  without 
soluble NGF or cytochrome c, and the mixtures were allowed to 
equilibrate  for  1  h  longer.  The  microfuge  tubes  containing  the 
mixtures were then  centrifuged,  the  supernatants aspirated, and 
the pellets washed and measured for radioactivity. The composition 
of the mixture is indicated below each bar. The results shown are 
from two separate experiments. In  each experiment three deter- 
minations were made for each of the combinations, and the data 
were normalized to the mean number of cpm obtained from the 
combination of  ~251-192-1gG and  NGF-Sepharose 4B  (bar a);  the 
actual  values  of  these  means  were  2,485  cpm  and  1,776  cpm. 
Values  plotted are  means  +  SEM. One-way analysis of variance 
with  Satterthwaithe's correction yielded P =  0.0015.  Numbers  in 
parentheses are  right tail  P values derived  from  Student's  t  test. 
* 192, lZSl-labeled 192-1gG; NGF-S, NGF-Sepharose 4B; ric A-S, ricin 
A chain-Sepharose 4B. 
the NGF receptor in the formation of the complex: replacing 
the solubilized SCG membrane preparation with either solu- 
bilized  rat  liver membrane (bar  h)  or  solubilized  rat  lung 
membrane (bar i) abolished the signal. 
We also performed analogous experiments using 1251-NGF, 
the n-octyl glucopyranoside-solubilized SCG membrane pro- 
teins, and  192-IgG covalently linked to Sepharose 4B.  The 
results of these solid-phase separation assays (data not shown) 
were similar to those presented in Fig.  l, and indicated the 
specific formation of a ternary complex of 125I-NGF, solubi- 
lized NGF receptor, and 192-IgG-Sepharose 4B. 
Filtration Binding Assay 
To corroborate further the specificity of 192-IgG binding 
to the  NGF receptor, we measured directly the binding of 
labeled  antibody  to  plasma  membrane-enriched  fractions 
prepared from various tissues,  known  to  contain  different 
amounts of NGF receptor, and correlated this to binding of 
labeled NGF to the same preparations. Fig. 2 shows that only 
membranes from SCG specifically bound significant amounts 
of ~zSI-NGF and ~251-192-A. Consistent with results obtained 
in binding assays using PC12 cells (14),  excess  192-IgG in- 3xlO 4 
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FIGURE 2  BindingofUSl-192-1gGand'251-NGF 
to rat tissue membrane preparations.  Labeled 
ligands (USl-192-1gG,  3.7 nM; 12SI-NGF,  0.5 nM) 
were incubated with membrane preparations 
(0.125  mg/ml  of  protein)  in  the  absence  or 
presence  of excess nonlabeled ligands (192- 
IgG, 440 nM; NGF, 480 nM) as described  in 
Materials and Methods. After 2 h at 25"C, the 
mixtures were passed through Millipore filters, 
and the filters were then washed and measured 
for radioactivity. The values are the means _+ 
SEM of triplicate determinations from a single 
experiment; two  other  experiments  yielded 
similar results. 
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creased ~25I-NGF binding, and excess NGF increased 125I-IgG 
binding. 
Retrograde Transport 
Intraocular injection  of ~251-192-IgG into  rats resulted in 
accumulation of radioactivity in the SCG located ipsilateral 
to the injected eye, whereas no accumulation was detected 
after injection of '25I-labeled monoclonal IgG against the EGF 
receptor of PC12 cells (data not shown). We therefore char- 
acterized the retrograde transport of labeled  192-IgG in ex- 
periments similar to those previously reported for NGF (16). 
Fig. 3 shows the time course of accumulation of 125I-192-IgG 
in the SCG. Radioactivity was detectable at 8 h,  reached a 
maximum level at 20 h, and declined rapidly thereafter. 
As increasing amounts of z25I-NGF are injected intraocu- 
larly,  the  quantity  accumulating in  the  ipsilateral SCG in- 
creases to reach a maximum value. This "functional satura- 
bility" is a consequence of the limited capacity in at least one 
of the  stages involved in  the  overall process of retrograde 
transport  (which  include  binding  of NGF  to  its  receptor, 
internalization  into the  neuron,  and  vectorial translocation 
through the axon to the soma). If 192-IgG binds to the NGF 
receptor, and is subsequently internalized and transported by 
the same mechanisms as is NGF, then the accumulation of 
antibody in the SCG should share the same saturation prop- 
erties. Various quantities of nonlabeled  192-IgG were com- 
bined with constant amounts of 12sI-192-IgG (24.5  pmol, 2.7 
x  107 cpm) to achieve samples of different specific radioactiv- 
ities. These samples were injected into the anterior eye cham- 
bers of rats, and the SCG were subsequently dissected. The 
radioactivity of each  SCG was measured separately. Fig.  4 
shows that the accumulation of 192-IgG reached a maximum 
of 1.5 fmol per ganglion, the same value found previously for 
NGF accumulation (16). 
The initial step in the retrograde transport of exogenously 
administered NGF is the binding of the injected NGF mole- 
cule  to  the  NGF receptor.  The  specificity of this  event  is 
inherent  to the interaction of a  receptor with its particular 
ligand. Therefore, as shown in Fig.  5 a, the co-injection of a 
150-fold  molar  excess  of nonlabeled  NGF  with  J25I-NGF 
eliminated  the  accumulation  of labeled  NGF in  the  SCG. 
Because the  binding of antibody and  its target molecule is 
also specific,  nonlabeled  192-IgG should compete with  ~25I- 
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FIGURE 3  Time course  of 12Sl-192-1gG accumulation in the SCG 
after intraocular injection. Radiolabeled 192-1gG (6 x  106 cpm in 2 
#l) was injected into the anterior eye chamber of each rat. At the 
indicated time intervals  both superior cervical  ganglia were dis- 
sected and the radioactivity of each was measured; from each rat 
a single value of specifically  accumulated radioactivity was calcu- 
lated by subtracting the cpm associated with the contralateral SCG 
(<120 cpm) from that of the ipsilateral SCG. Values plotted are the 
means + SEM of 6-7 animals. 
192-IgG for binding to the NGF receptor. The data of Fig. 5 
demonstrate this competition: a 35-fold molar excess of non- 
labeled antibody co-injected with  J251-192-IgG reduced  the 
accumulation of radioactivity in the SCG. We were unable to 
obtain a greater ratio ofnonlabeled to labeled 192-IgG because 
of the limited solubility of 192-IgG (7.5 mg/ml) and the small 
volume that can be injected (5 ul). 
Consistent with the data of the in vitro binding assays (14), 
NGF and  192-IgG failed  to  compete with  each  other  for 
retrograde  transport;  there  appears  to  have  been,  in  fact, 
mutual enhancement of  accumulation (Fig. 5, a and b). These 
results reflect the fact that NGF and  192-IgG can bind non- 
competitively to the NGF receptor as the first step in retro- 
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protein  should  allow co-transport of NGF and  192-4,  and 
therefore  injection  of  ~:SI-NGF  and  ~:sI-192-IgG  together 
should lead to accumulation of both in the SCG. The results 
shown  in  Fig.  5 c and  Fig.  6  support this.  The  amount of 
radioactivity that accumulated when JESI-NGF and  1251-192- 
IgG were injected together is equal to the sum of the quantities 
obtained when they were injected alone (Fig.  5 c). The auto- 
radiograph (Fig.  6)  shows that intact  ~zsI-192-IgG and  ~2sI- 
NGF were both present in the SCG when these radiolabeled 
ligands were co-injected, thus verifying that they were trans- 
ported simultaneously. The extraneous bands of lanes 4,  5, 
and  6  are  degradation  products  of  192-IgG,  presumably 
formed in the SCG. 
The retrograde transport of 192-IgG appears to be species 
specific (Table I). There was no accumulation of radioactivity 
following intraocular injection of 125I-  192-IgG in mice, gerbils, 
hamsters, and  guinea pigs.  Separate injections  of ~251-NGF 
did lead to the accumulation of label in the ipsilateral SCG 
NGF  192-IgG 
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Concentration dependence of  NGF  or  192-1gG accu- 
mulation in the SCG. Labeled ligand (1251-NGF or 12Sl-192-1gG)  was 
combined with different amounts of  nonlabeled ligand (NGF  or 
192-1gG, respectively) to attain solutions of particular specific activ- 
ities. 5/A of solution was injected into the anterior eye chamber of 
each rat. After 16 h both SCG were dissected and the radioactivity 
of each  was measured.  The  value of  the contralateral SCG  was 
subtracted  from  that  of  the  ipsilateral, and  this  difference  was 
converted to molar values of injected ligand. Plotted values are the 
means 4- SEM of 6-7  rats. The results with NGF are recalculated 
from a previous study (16). 
of these species,  verifying that  the  injection  technique  was 
sound. 
DISCUSSION 
The initial description of monoclonal antibody  192-IgG es- 
tablished its effect of increasing the affinity of NGF binding 
to the NGF receptor of PC12  cells,  and demonstrated that 
192-IgG binds to the same number of sites as does NGF and 
that  it  does  not  bind  NGF  (14).  In  this  paper  we  have 
confirmed the specific binding of 192-IgG to the NGF recep- 
tor,  both  in  vitro  and  in  vivo.  Results  of the  solid-phase 
separation assay demonstrated that  192-IgG can form a ter- 
nary complex with solubilized NGF receptor and NGF. The 
result  that  soluble  NGF,  but  not  soluble  cytochrome  c, 
blocked the association of ~25I-192-IgG  with the NGF-Sepha- 
rose showed that this association involved the specific inter- 
action of NGF with its receptor. The competition by nonla- 
beled  192-IgG,  but  not  by an  irrelevant  monocional  IgG, 
attested to the specificity of the interaction of 192-IgG with 
the  NGF-binding  moiety. The  fact that  solubilized plasma 
membrane protein from rat SCG, but not liver or lung, was 
necessary and  sufficient for the  association  of ~251-192-IgG 
with the NGF-Sepharose 4B pellet argues further that it was 
the NGF receptor which linked these two species.  The filtra- 
tion  binding  assay  showed  that  the  192-lgG  binds  to  an 
epitope that is present only in certain tissues; the distribution 
of this epitope is consistent with that expected of the NGF 
receptor. 
The accumulation within the neuronal cell bodies (in the 
SCG) of a protein administered to the nerve termini (at the 
iris)  requires the  following processes: binding to  receptors, 
internalization,  and  active retrograde transport.  The  retro- 
grade axonal transport of 192-IgG displayed a  time course 
similar to that described for NGF (16). In particular, 192-IgG 
accumulation was detectable between 4 and 8 h after intra- 
ocular injection,  indicating the  same rate of transport (~3 
mm/hour, assuming a 2-cm distance between the iris and the 
SCG) as that of NGF. Likewise, the value of maximum 192- 
IgG accumulation,  1.5  fmol,  equals  the  reported  value  of 
maximum NGF accumulation (16). These results are consist- 
ent  with  the  hypothesis  that  192-IgG  binds  to  the  NGF 
3poo 
E 
U 
U 
>,  .0 
 ooo, 
n 
.>  IOOC 
0 
.0  i 
(p(O.OlO) 
I, 
{p(O.244) 
"T- 
"-1-" 
(p<O,O005) 
,  r---1 
~ast_.-NG  F  '2SI-NGF  I=~.NGF  t=sI-19 2  'zsl.19  2  'z~I-19  2 
•  11-  -I.  ÷  4" 
NGF  192  192  NGF 
'~ I-NGF 
÷ 
'asT.19  2 
FIGURE  S  Specificity  of  retrograde transport 
and co-transport of NGF and  192-1gG. Radio- 
labeled NGF (2 x  106 cpm, 2 pmol) or 192-1gG 
(8 x  106 cpm, 5 pmol) was injected alone, or 
with nonlabeled NGF  (500  pmol) or  192-1gG 
(160 pmol), or together, as indicated below the 
graphs. The volume of each injection was 5/A. 
After  16  h both SCG were dissected  and the 
radioactivity of each was measured. The value 
of the contralateral SCG was subtracted from 
that of the ipsilateral for each pair. Values rep- 
resent the mean 4- SEM of 5 -7 rats. One-way 
analysis of variance with Satterthwaithe's cor- 
rection yielded P =  0.0001  for the data of a, 
and P =  0.0003  for the data of b.  Numbers in 
parentheses indicate right tail P values derived 
from Student's  t test. 
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radiography  of  SCG  with  accu- 
mulated  *zSI-NGF  and  ~2Sl-192- 
IgG.  The  ipsilateral  SCG  of  rats 
injected  intraocularly with  radio- 
labeled  ligands (see  Fig.  5)  were 
homogenized  in  1%  SDS  and 
electrophoresed on a  7-20% ex- 
ponential  gradient  gel.  The  gel 
was stained with  Coomassie Bril- 
liant Blue R, destained, dried, and 
exposed  to  Kodak  X-Omat  film 
foE 4  d.  Lane  1,  ~251-NGF; lane 2, 
SCG of rat injected with ~2SI-NGF; 
lane 3,  SCG  of  rat  injected  with 
~St-NGF  and  nonlabe/ed  192- 
IgG;  lane  4,  SCG  of  rat  injected 
with  ~2SI-NGF  and  12Sl-192-1gG; 
lane 5,  SCG  of  rat  injected  with 
'2s1-192-1gG  and  nonlabeled 
NGF;  lane 6, SCG of rat injected 
with ~2Sl-192-1gG; lane 7, 12s1-192- 
IgG. The molecular weight stand- 
ards  were  phosphorylase  B 
(92,500);  bovine  serum  albumin 
(66,200); ovalbumin (45,000); car- 
bonic  anhydrase  (31,000);  soy- 
bean trypsin inhibitor (21,500); ly- 
sozyme  (14,400). 
TABLE  I.  Comparison of 192-1gG Retrograde Transport in Rat and 
Non-Rat Species 
Specific accumulation*  Specific accumulation 
of ~2Sl-192-1gG in  of 12SI-NGF in 
Species  ipsilatera/SCG  ipsi/atera/SCG 
cpm  cpm 
Rat  1,588.5  _  240.8 (4)  1,267.8 4- 69.2 (6) 
Mouse  3.0  4-  4.1  (4)  -- 
Gerbil  0.6  ±  4.1  (7)  464 (2) 
Hamster  -0.3  ±  3.0 (8)  475 (2) 
Guinea pig  42.5  4-  35.5 (4)  2,835 (2) 
2/A of 12Sl-t  92-1gG (2 x  106 cpm) or of lzSI-NGF (2 x  106 cpm) was injected 
into the anterior eye chamber of each animal.  The SCG  were dissected 
after  16 h for rats and guinea pigs, 8 h for gerbils and hamsters, and 6 h for 
mice. 
* Specific accumulation is defined as the difference:  (counts per minute of 
ipsilateral  SCG) -  (counts  per minute of contralateral  SCG). Values are 
means _+ S~M; values in parentheses indicate the number of experimental 
animals. 
receptor, becomes internalized, and is transported by the same 
mechanisms as is  NGF.  The internalization and  retrograde 
axonal transport of 192-IgG in the presence of only the minute 
quantity of endogenous NGF (i.e., without any experimental 
administration of NGF)  raises the possibility that the NGF 
receptor is continuously internalized and retrogradely trans- 
ported, even in the absence of bound NGF. Such a constitu- 
tive transport of the NGF  receptor is also suggested  by the 
observation that  125I-labeled NGF  is specifically bound and 
retrogradely transported from the crush  site  of axotomized 
sciatic  nerve  in  rats  (24,  28)  and  newts  (24).  Continuous 
internalization  of receptor  proteins  independent  of ligand 
binding has been proposed for at least one other system, that 
of the low density lipoprotein receptor of human fibrobtasts 
(29). 
The retrograde transport of 192-IgG therefore can serve as 
an  in  vivo binding assay for the  monoclonal antibody.  We 
interpret the lack of retrograde transport of 192-IgG in mice, 
gerbils,  hamsters, and guinea pigs as a  manifestation of the 
species specificity of the monoclonal antibody (i.e.,  192-IgG 
binds  to an  epitope  found  only on  the  rat  NGF  receptor). 
This specificity was also observed in results of the filtration 
binding  assay  in  which  t2SI-labeled  192-IgG  did  not  bind 
specifically to mouse SCG membrane preparations (data not 
shown). 
The binding characteristics of 192-lgG are similar to other 
receptor-directed  antibodies,  both  monoclonal  and  poly- 
clonal, that bind to determinants outside of the ligand-binding 
sites. For example, Richert et al. have described a monoclonal 
IgG3  directed against the  EGF  receptor of A431  cells that 
fails to inhibit EGF binding (30),  and  Schreiber et at.  have 
documented  a  monoclonal IgG2a  that  immunoprecipitates 
the EGF receptor but does not interfere with its binding of 
EGF (31).  Jacobs et al.  (32)  and Grunfeld (33) have shown 
that polyclonal antibodies directed against the insulin receptor 
exert biological effects on the receptor without blocking in- 
TANIUCHI AND JOHNSON Anti-NGF  Receptor  Antibody  1 ] 05 sulin binding.  The noncompetitive binding of 192-IgG  and 
NGF to the NGF receptor makes this monoclonal antibody 
uniquely suitable for probing the NGF receptor without in- 
hibiting  the  interaction  of the  receptor  with  its  hormone 
ligand. Because of this noncompetitive nature of 192-IgG and 
NGF  binding,  experimental  perturbation of the biology of 
neurons using 192-IgG would implicate mechanisms involv- 
ing the receptor directly, exclusive of its interaction with NGF. 
In addition, it should be possible to use 192-IgG as a specific 
histological ligand for the NGF receptor irrespective of the 
NGF occupation state of the receptor. 
The specific retrograde transport of 192-IgG confirms that 
it can bind to the NGF receptor in vivo.  This monoclonal 
antibody  can therefore  be  used  as a  specific  probe  for the 
NGF receptor, both in the intact rat to study the role of the 
receptor in mediating the biological effects of NGF,  and in 
tissues to detect immunohistochemically the presence of the 
receptor.  It can also serve to target particular molecules to 
NGF receptor-bearing cells and thereby make possible exper- 
iments to manipulate these neurons specifically. For example, 
a hybrid molecule of 192-IgG linked to the toxic ricin A chain 
would bind to an NGF receptor-containing cell via the anti- 
body moiety, then, following internalization, kill the cell via 
inhibition of protein synthesis by the ricin A chain. 
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